MedTrace Logo

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

NCT04974723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22054

Last updated 2024-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the real-world effectiveness and cardiovascular safety of ABL compared with TPTD during the 18-month period after treatment initiation in propensity score (PS)-matched cohorts

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DRUG

Abaloparatide

Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)

DRUG

Teriparatide

Teriparatide subcutaneous (TPTD; Forteo®)

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • Radius Health, Inc.

    lead INDUSTRY

Eligibility

Min Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974723 on ClinicalTrials.gov